Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global...

Monday, June 2, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference, scheduled for June 9, 2025. The management will engage in a fireside chat presentation, which will be available via live webcast and archived for 14 days. This event underscores Alkermes' focus on investor relations and its portfolio in neuroscience.
Price reaction · baseline $30.61 (2025-05-30 close) · clean, no other ALKS news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is actively engaging with investors at a major healthcare conference.
  • The company showcases its commitment to transparency and communication.
  • Participation in the conference highlights Alkermes' innovative approach in neuroscience.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46 th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT ( 3:00 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes' website at www.alkermes.com .

Frequently Asked Questions

When is Alkermes participating in the conference?

Alkermes will participate in the conference on June 9, 2025.

How can I access the Alkermes presentation?

The presentation can be accessed via live webcast on Alkermes' website.

What is the focus of Alkermes' portfolio?

Alkermes focuses on developing innovative medicines for neurological disorders.

Where is Alkermes headquartered?

Alkermes is headquartered in Dublin, Ireland.

ShareAdd on Google
Tags: ALKS Viatris Investor Conferences Healthcare Alkermes Goldman Sachs healthcare conference biopharmaceuticals neuroscience
Last updated: Jun 2, 2025

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
N1539Phase 2
Hysterectomy →

Catalyst track record

+29%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →